Evaluation of Drug—Drug Interactions in EGFR-Mutated Non-Small-Cell Lung Cancer Patients during Treatment with Tyrosine-Kinase Inhibitors

(1) Background. The onset of a drug–drug interaction (DDI) may affect treatment efficacy and toxicity of advanced non-small-cell lung cancer (aNSCLC) patients during epidermal growth factor receptor (EGFR) tyrosine-kinase inhibitor (TKI) use. Here we present the use of Drug-PIN(®) (Personalized Inte...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:J Pers Med
Prif Awduron: Occhipinti, Mario, Brambilla, Marta, Galli, Giulia, Manglaviti, Sara, Giammaruco, Maristella, Prelaj, Arsela, Ferrara, Roberto, De Toma, Alessandro, Proto, Claudia, Beninato, Teresa, Zattarin, Emma, Lo Russo, Giuseppe, Gelibter, Alain Jonathan, Simmaco, Maurizio, Preissner, Robert, Garassino, Marina Chiara, De Braud, Filippo, Marchetti, Paolo
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: MDPI 2021
Pynciau:
Article
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC8157378/
https://ncbi.nlm.nih.gov/pubmed/34069851
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/jpm11050424
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg